News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 23, 2016, 05:30 ET CSL Behring Announces Immunoglobulin Research Grant Winners

 CSL Behring announced today at the Peripheral Nerve Society's Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow,...


Jun 20, 2016, 09:00 ET AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.

 Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain],...


May 26, 2016, 15:20 ET U.S. FDA Approves CSL Behring's AFSTYLA® -- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor...


May 13, 2016, 10:15 ET CSL's Paul Perreault Receives Healthcare CEO Enterprise Award from Philadelphia Alliance for Capital and Technologies

 Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL...


May 11, 2016, 13:30 ET IDELVION® -- CSL Behring's Innovative Therapy for Hemophilia B Patients -- Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration

 CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for...


May 11, 2016, 11:00 ET European Commission Approves IDELVION® --CSL Behring's Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

 CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting...


Apr 25, 2016, 09:00 ET CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions

 CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical...


Apr 13, 2016, 09:12 ET CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia

 "Treatment for All is the Vision for All" is the World Federation of Hemophilia's (WFH) global message for World Hemophilia Day this year...


Mar 21, 2016, 09:18 ET IDELVION® for Hemophilia B Now Available in the U.S.

 CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting...


Mar 15, 2016, 09:30 ET CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies

In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation's new PI Voices,...


Mar 09, 2016, 09:00 ET CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them...


Mar 04, 2016, 20:13 ET U.S. FDA Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX...


Feb 23, 2016, 09:30 ET First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia

 Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been...


Feb 02, 2016, 08:00 ET CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S.

 CSL Behring's U.S. locations in King of Prussia and Kankakee, Il., and its subsidiary, CSL Plasma headquartered in Boca Raton, Fla., raised...


Dec 22, 2015, 09:00 ET CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A

 Global biotherapeutics leader CSL Behring announced today that the company has submitted its Marketing Authorization Application (MAA) to the...


Dec 21, 2015, 09:01 ET CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients

 Global biotherapeutics leader CSL Behring announced today that the company has submitted its new drug application to Japan's...


Dec 10, 2015, 18:41 ET CSL Behring rozširuje prevádzky do Ruska

Pobočka v Moskve posilní prísľub spoločnosti CSL Behring poskytovať pacientom so zriedkavými...


Dec 10, 2015, 13:31 ET CSL Behring étend ses opérations en Russie

L'ouverture à Moscou renforce la promesse de CSL Behring de livrer ses thérapies de classe mondiale aux patients atteints de maladies...


Dec 10, 2015, 10:28 ET CSL Behring expandiert Geschäftsaktivitäten in Russland

Moskauer Eröffnung bekräftigt das Engagement von CSL Behring, seine erstklassigen Therapien für Patienten mit seltenen und schweren...


Dec 10, 2015, 09:42 ET CSL Behring ekspanduje do Rosji

Otwarcie biura moskiewskiego wzmacnia obietnice CSL Behring, iż będzie dostarczała światowej klasy środki lecznicze dla...


Dec 10, 2015, 09:22 ET CSL Behring expanduje do Ruska

Zahájení činnosti v Moskvě je posílením slibu společnosti CSL Behring poskytovat své...


Dec 10, 2015, 03:00 ET CSL Behring expande sus operaciones a Rusia

La apertura de Moscú refuerza la promesa de CSL Behring para ofrecer terapias de clase mundial para pacientes con enfermedades raras y graves...


Dec 08, 2015, 08:00 ET CSL Behring Expands Operations to Russia

 Global biotherapeutics leader CSL Behring announced today its latest geographic expansion to provide more patients with greater access to...


Dec 07, 2015, 11:00 ET CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition

 Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and...


Dec 02, 2015, 09:00 ET CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition

 CSL Behring announced today that it will present several abstracts from its recombinant coagulation factor development programs at the...